Oral Presentation Accepted for Late Breaking Session of the National Kidney Foundation Spring Clinical Meeting
Renalytix AI plc, the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that data from a study highlighting the health economic benefits associated with KidneyIntelX testing in diabetic kidney disease populations (DKD) will be presented at the National Kidney Foundation Spring Clinical Meeting. An abstract summarizing key results will be published in the peer reviewed journal, the American Journal of Kidney Disease.
Recommended AI News: Amazon Go Grocery Opens Largest Contactless Retail Store in Seattle
National Kidney Foundation Spring Clinical Meeting (March 26, 2020)
Thomas Goss, PharmD, Senior Vice President, Boston Healthcare Associates, will deliver a presentation titled Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression during the Late Breaking Abstract session at the National Kidney Foundation’s Spring Clinical Meeting. The presentation will highlight the significant cost savings associated with the implementation of KidneyIntelX in large health care system patient populations in the United States. The presentation is based on a comprehensive economic model developed by Boston Healthcare Associates utilizing peer reviewed clinical data to estimate the costs associated with chronic kidney disease progression in the U.S. The presentation session will be held on Thursday, March 26, 2020 at 4:15 PM ET. A summary of the presentation results will be made available on the Company’s website.
“The results suggest substantial cost savings can be achieved using KidneyIntelX to assess CKD patient populations at risk of rapid kidney function decline and/or kidney failure under a number of different scenarios tested,” said Thomas Goss, Senior Vice President at Boston Healthcare Associates Inc.
Recommended AI News: AiThority Interview with Liam McCance, Chief Strategy Officer at Singlife
An abstract summarizing the results will also be published in the May 2020 issue of the American Journal of Kidney Disease (www.ajkd.org), the official journal of the National Kidney Foundation, which is recognized worldwide as a leading source of information devoted to clinical nephrology practice and clinical research.
NKF’s Spring Clinical Meeting gathers more than 3,000 nephrology healthcare professionals from across the United States to learn about the newest developments related to all aspects of nephrology practice. Due to the coronavirus and coronavirus disease (COVID-19) outbreak in the United States the meeting is being held as a live virtual event in 2020. Sessions can be accessed through the conference website.
Recommended AI News: Bravo! In Tough Times, Resolute PR Firms Stand Their Ground